logo-loader
viewCannPal Animal Therapeutics Ltd

CannPal Animal Therapeutics receives approval to advance clinical studies

Results from the phase Ib study are expected during this September quarter.

cat lying on a dog
The cannabis-derived pain control drug candidate CPAT-01 is targeting cats and dogs

CannPal Animal Therapeutics Ltd (ASX:CP1) has received ethics approvals to advance the development of its lead drug candidate, CPAT-01, a pain control in dogs.

Phase Ib is a continuation of research into CPAT-01, an innovative cannabis-derived pain control being developed for both cats and dogs.

Set to commence this month, phase Ib of the pharmacokinetic and safety study has recruited 48 dogs for the study.

READ: CannPal Animal Therapeutics positioned in a growing animal health market

CannPal's managing director Layton Mills said: “We’re very pleased to have received ethics approval for our phase Ib study for CPAT-01.

“The speed with which CannPal has moved to the next stage of our research is indicative of our commitment to progressing our clinical development plans on time.

“We look forward to further updating the market on the results of this study, which are expected in Q3 2018.”

Study also assessing tolerability

The study design will be assessing additional pharmacokinetic and safety parameters, including tolerability at five times the estimated dose, and early dose ranging confirmation.

The company is also evaluating the cannabinoid impact on identified gene expression targets to identify underlying mechanisms of action.

Quick facts: CannPal Animal Therapeutics Ltd

Price: 0.13 AUD

ASX:CP1
Market: ASX
Market Cap: $12.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear,...

on 25/6/18

2 min read